6 research outputs found
Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0653-1"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides<u></u></p
Kaplan-Meier Curves of Progression-Free Survival (PFS) and Overall Survival (OS) Distributions after Vandetanib with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients.
<p><b>A</b>, PFS distribution for all patients (n = 27). <b>B</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20). <b>C</b>, PFS distribution for all patients (n = 27). <b>D</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20).</p
Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and 15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.
<p>Data are shown as medians and interquartile ranges (in square brackets) compared to baseline levels. <i>P</i>-values are from the exact paired Wilcoxon test, before and after adjustment for multiple comparisons over time using the method of Genovese at al. VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; PlGF, placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2, soluble VEGF receptor-2; SDF-1α, stromal cell-derived factor-1-alpha; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.</p
Waterfall Plot.
<p>Best response analysis after vandetanib with cetuximab and irinotecan limited to patients with confirmed KRAS wild-type metastatic colorectal cancer and at least 1 restaging imaging scan.</p
Adverse Events (based on worse toxicity by patient).
*<p>includes magnesium, potassium, sodium and calcium changes.</p